CJC-1295 No Dac + Ipamorelin

Buy CJC-1295 No Dac + Ipamorelin Online

CJC-1295 No DAC + Ipamorelin combines a GHRH-related peptide with a growth hormone secretagogue. The combination is studied in the context of GH and IGF-1 signaling, with each peptide acting through a different part of the growth hormone regulatory system.

Product Information

CJC-1295 is a synthetic growth hormone-releasing hormone analogue, while Ipamorelin is a selective growth hormone secretagogue. Human studies of CJC-1295 have demonstrated sustained increases in GH and IGF-1, while research on Ipamorelin has focused on GH release. However, the exact CJC-1295 No DAC + Ipamorelin combination does not have an established clinical dosing protocol or robust combination-specific human trial evidence.

How It Works

The two peptides stimulate the GH axis through complementary pathways. CJC-1295 acts through GHRH signaling, while Ipamorelin activates the growth hormone secretagogue receptor pathway, potentially producing a stronger GH-release signal than either pathway alone.

POTENTIAL BENEFITS

1. Growth Hormone Research

CJC-1295 has produced sustained increases in circulating GH in controlled human research. Combining it with a GH secretagogue is therefore of interest in studies examining coordinated stimulation of the GH axis.

2. IGF-1 Research

Human CJC-1295 studies have demonstrated increases in IGF-1 following administration. Because IGF-1 is one of the principal downstream mediators of GH activity, this makes the combination relevant to GH/IGF-1 pathway research.

3. Muscle Recovery Research

GH and IGF-1 signaling are closely involved in protein synthesis, tissue remodeling, and muscle physiology. Research involving CJC-1295 and Ipamorelin therefore frequently focuses on muscle and recovery-related pathways, although combination-specific human evidence remains limited.

4. Dual-Pathway Research

The key research rationale behind the combination is its complementary mechanism: GHRH signaling from CJC-1295 together with secretagogue activity from Ipamorelin. This provides a useful model for investigating regulation of pulsatile GH secretion.

Dosage

Human studies of CJC-1295 have evaluated doses including 30 and 60 micrograms/kg, while separate CJC-1295 studies have examined 60 and 90 micrograms/kg. These were controlled clinical research protocols and primarily involved CJC-1295 itself, not the No DAC + Ipamorelin combination. No established human dosage exists for this exact combination.

Side Effects

Potential concerns with growth-hormone-axis peptides include changes in glucose metabolism, fluid retention, headache, injection-site reactions, and alterations in GH/IGF-1 signaling. The long-term safety profile of the specific CJC-1295 No DAC + Ipamorelin combination remains uncertain.

References

1. Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295.
3. 2026 review of peptides modulating the GH-IGF-1 axis.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.